17,261 trials
Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
Primary: Progression-Free Survival (PFS) in Patients With Non-germinal Center B-cell-like (Non-GCB) Diffuse Large B-cell Lymphoma (DLBCL) — NA; NA months
Ulcer · Venous Ulcer · Skin Ulcer
Primary: Logarithm of Percentage of Baseline Ulcer Size — 3.6043; 3.5030 Mean of log (percentage of baseline area — p=0.652
Healthy Volunteers
Primary: Ceftriaxone PK Maximum Observed Plasma Concentration (Cmax) With (Period 2) and Without (Period 1) SYN-004. — 137,800.0; 178,600.0; 143,800.0; 169,200.0 ng/mL
Brain and Central Nervous System Tumors
Primary: Maximum Tolerated Dose (MTD) of Everolimus (RAD001) in Combination With Temozolomide (TMZ) and 3D-conformal Radiotherapy (RT) or Intensity-modulated Radiotherapy (IMRT)…
Multiple Myeloma
Primary: Number of Participants With Grade 3 or Grade 4 (G3/4) Infusion Reactions by the End of Treatment Cycle 2 — 0 Participants
Thrombosis
Primary: Incidence of Arterial Bleeding — 1 Participants
Major Depressive Disorder
Primary: Change From Baseline in Baseline-adjusted (Montgomery-Asberg Depression Scale) MADRS Score at the End of Treatment. — -6.1396; -6.0076; -11.3762 Scores on a scale
Chronic Iron Overload
Primary: CL/F — 8.3 litre/h
Lupus Nephritis
Primary: Complete and Partial Response Rate — 55 Percentage of participants
HCV Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 98.0; 70.7; 100.0 Percentage of participants
Tuberculosis
Primary: Number of Subjects With Solicited Local Symptoms — 37; 3; 3; 0 Subjects
Crohn's Disease
Primary: Percentage of Participants With Clinical Response-100 (as Defined by a Decrease in Crohn's Disease Activity Index [CDAI] Score of at Least 100 Points From Baseline) or…
Alzheimer Disease · Dementia
Primary: Safety Assessments: Number of Participants With Adverse Events — 07; 02 Participants
Nicotine Dependence
Primary: 4-week, Continuous Tobacco Abstinence at the End of the 6-week, Double Blind, Treatment Phase — 0; 0 Participants
Epilepsy
Primary: Mean Trough Plasma Concentration at 3rd Level for Age Range ≥1 Month to <2 Years — 0.825 ug/mL